First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
about
Novel drugs that target the metabolic reprogramming in renal cell cancerThe mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trialsPharmacodynamic Biomarker Development for PI3K Pathway TherapeuticsPI3K/Akt/mTOR inhibitors in breast cancerJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesA high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma CellsA first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancerPrevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.Inhibiting 4EBP1 in glioblastoma.Targeting mTOR for the treatment of B cell malignancies.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.Autophagy: controlling cell fate in rheumatic diseases.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.mTORC1 and mTORC2 in cancer and the tumor microenvironment.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer.Uncoupling TORC2 from AGC kinases inhibits tumour growth.The PI3K Pathway in Human Disease.Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.A small molecule inhibitor of Rheb selectively targets mTORC1 signaling.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.
P2860
Q26740187-EF76F8A6-B295-43BF-8BA0-28A933E923B1Q26751155-7F34033B-310F-4335-8BA2-A7DB7A2E52B4Q26766292-AA383838-6B2B-4244-86D8-CB97BDB8186BQ26771394-F38E4D47-FBF9-4C63-8F57-5B4977C5853DQ28071388-CDEE67A5-B8D0-496E-9F05-4A9894EF3C78Q30396975-EAABC0C5-8FDF-47C5-B881-71153F65709CQ33798463-BDD3C7D5-C48E-4447-8B11-B91CF571458BQ36992455-AB26A246-D6FD-4E67-AE78-F2D9CA552FFFQ37004340-A640D5C6-E45F-4E1D-9DA2-010D947E8534Q37174723-3D790D9C-8DA2-4654-9F0F-001638B8B986Q37203121-090C42D7-C53B-4F38-8B8A-C5786B7A56CFQ37277855-8B48F090-C5AD-4AD8-BC10-A2702C0FEE02Q37687122-9EABD4CD-69AF-4428-A0EF-A22A5502C3B4Q38262117-E47A9C9F-CD21-430C-BF51-DD1D48467FDBQ38543837-90429C33-1B08-4826-B0B8-08748C250117Q38659417-016FDD4A-13A7-4348-BCAD-C081D164CB76Q38709825-FF7AFCEF-7EEF-475C-9CD4-EE6E0F2CF81AQ38711763-77102596-3D8D-4122-97DC-EEEA4A3F416EQ38786234-AA2F64DF-C267-4DE3-B8D6-EC5ADED8A1D9Q38873681-13A56392-0060-48F1-B8F3-018443605ADDQ38955246-F46F5B6F-EEC8-4004-BBE6-48907EEADD9AQ38982579-A4096B7E-1206-42A6-B565-21DE8DF668F0Q39023175-AEE3CDE5-A130-4B88-AE6A-80625231CFACQ41195708-29471EFB-95A4-4275-8470-C7BEB3A700A3Q42359443-8B35E989-8869-4ECA-9281-1B028D8070C7Q44268034-12994525-3CCB-4675-94D8-7E0225E5CD8EQ46156033-1C5FB820-CEFF-402A-A8AD-7EAF125E3EA3Q46546002-3B27208D-1B29-4D2C-8027-01F902D07F64Q47835201-9D874D4D-BAF0-456B-B5A9-6C3BCA5E203AQ48123819-CB42A978-DF2E-4646-B086-BC29F2F71C0DQ49198717-C7803AB7-B872-4325-9F28-A63B758FBF5CQ49393542-E62B766D-5BE1-4A5C-AC55-4368C7E4D1D7Q49787386-770F6086-5CDE-4865-AE8B-8F14182A6AAC
P2860
First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@ast
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@en
type
label
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@ast
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@en
prefLabel
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@ast
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@en
P2093
P2860
P50
P1476
First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.
@en
P2093
Bristi Basu
Christopher Womack
Elisabeth Oelmann
Elizabeth A Harrington
Graham Bigley
Johann S de Bono
Malcolm Ranson
Maria Cavallin
Martina Puglisi
Stephen Green
P2860
P304
P356
10.1158/1078-0432.CCR-14-2422
P407
P577
2015-03-24T00:00:00Z